Supply: Yale Most cancers Heart
20 years after uncovering the function of EGFR mutations in lung most cancers, scientists are nonetheless grappling with lingering analysis questions.
Audio system on the Lung Most cancers SPORE Workshop’s tribute session on the current panorama of EGFR-driven lung most cancers mentioned potential methods to stop or overcome resistance to EGFR inhibitors, how lengthy sufferers must be on them, and find out how to improve entry to remedy.
Suresh Ramalingam of Winship Most cancers Institute spoke in regards to the part III LAURA trial exploring an indefinite course of osimertinib (The Most cancers Letter, June 7, 2024), and Robert Winn of VCU Massey Complete Most cancers Heart shared the rostrum with Rev. Tyron Williams, pastor at a church within the Northern Neck area of Virginia, to debate the significance of working intently with communities underrepresented in medical trials.
The workshop, hosted by Yale Most cancers Heart and Smilow Most cancers Hospital June 12-13, was held in commemoration of the twentieth anniversary of the invention of EGFR in lung most cancers, which launched the period of personalised medication in superior non-small cell lung most cancers, resulting in a dramatic shift in remedy outcomes.
Chaired by Roy S. Herbst, Ensign Professor of Medication (Medical Oncology) and professor of pharmacology, deputy director, Yale Most cancers Heart, and chief of medical oncology at Yale Most cancers Heart and Smilow Most cancers Hospital, and Katerina Politi, Joseph A. and Lucille Ok. Madri Professor of Pathology at Yale Most cancers Heart, the workshop included displays from featured audio system, panel discussions, and posters classes.
A recording of this tribute session on “The Current” is now obtainable on the Most cancers Historical past Venture.
The Lung Most cancers SPORE Workshop’s tribute session on the early days of EGFR can be obtainable, together with a visitor editorial by Yale’s Politi and Herbst.
Watch the EGFR tribute session on the current on the Most cancers Historical past Venture:
VIDEO: NCI Annual Lung Most cancers SPORE Workshop 2024: EGFR – Current
By Yale Most cancers Heart, July 12, 2024
In a session chaired by Sarah Goldberg, MD, MPH, affiliate professor of medication (medical oncology) at Yale Most cancers Heart, panelists and audio system targeted on well being disparities, the significance of early detection and screening, the function of immuno-oncology, and featured affected person and group advocates who shared their experiences.
Audio system included:
- Pasi Jänne, MD, PhD, Professor of Medication, Harvard Medical College,
- Suresh Ramalingam, MD, Government Director, Winship Most cancers Institute of Emory College; Affiliate Vice President for Most cancers, Woodruff Well being Sciences Heart,
- Helena Yu, MD, Affiliate Attending Doctor, Memorial Sloan Kettering Most cancers Heart,
- Robert Winn, MD, Director and Lipman Chair in Oncology, VCU Massey Complete Most cancers Heart,
- Rev. Tyron Williams, DDiv, MDiv, group advocate, VCU Massey Complete Most cancers Heart,
- Diane Legg, affected person advocate, Massachusetts Common Hospital.
- The session concluded with a panel dialogue that includes:
- Mark Lemmon, PhD, FRS, Alfred Gilman Professor and Chair of Pharmacology
- Christine Lovly, MD, PhD, Ingram Affiliate Professor of Most cancers Analysis; Affiliate Professor of Medication (Hematology/Oncology)
- Harold Varmus, MD, Lewis Thomas College Professor of Medication, Weill Cornell Medical Faculty
- Kwok-Kin Wong, MD, PhD, The Anne Murnick Cogan and David H. Cogan Professor of Oncology, Division of Medication, NYU Langone Well being
This column options the newest posts to the Most cancers Historical past Venture by our rising checklist of contributors.
The Most cancers Historical past Venture is a free, web-based, collaborative useful resource meant to mark the fiftieth anniversary of the Nationwide Most cancers Act and designed to proceed in perpetuity. The target is to assemble a strong assortment of historic paperwork and make them freely obtainable.
Entry to the Most cancers Historical past Venture is open to the general public at CancerHistoryProject.com. You may as well comply with us on Twitter at @CancerHistProj, or comply with our podcast.
Is your establishment a contributor to the Most cancers Historical past Venture? Eligible establishments embody most cancers facilities, advocacy teams, skilled societies, pharmaceutical corporations, and key organizations in oncology.
To use to grow to be a contributor, please contact admin@cancerhistoryproject.com.
